Dianthus Therapeutics, Inc.
DNTH
$24.33
$0.923.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 193.00K | 1.16M | 1.33M | 2.17M | 1.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 193.00K | 1.16M | 1.33M | 2.17M | 1.86M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 193.00K | 1.16M | 1.33M | 2.17M | 1.86M |
| SG&A Expenses | 8.87M | 7.34M | 6.83M | 6.53M | 6.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.12M | 34.34M | 33.24M | 32.07M | 24.07M |
| Operating Income | -34.93M | -33.18M | -31.92M | -29.90M | -22.20M |
| Income Before Tax | -31.63M | -29.51M | -28.44M | -25.17M | -17.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.63M | -29.51M | -28.44M | -25.17M | -17.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.63M | -29.51M | -28.44M | -25.17M | -17.61M |
| EBIT | -34.93M | -33.18M | -31.92M | -29.90M | -22.20M |
| EBITDA | -34.90M | -33.15M | -31.89M | -29.88M | -22.18M |
| EPS Basic | -0.88 | -0.82 | -0.81 | -0.74 | -0.51 |
| Normalized Basic EPS | -0.57 | -0.55 | -0.50 | -0.47 | -0.33 |
| EPS Diluted | -0.88 | -0.82 | -0.81 | -0.74 | -0.51 |
| Normalized Diluted EPS | -0.57 | -0.55 | -0.50 | -0.47 | -0.33 |
| Average Basic Shares Outstanding | 35.82M | 35.79M | 35.03M | 34.24M | 34.23M |
| Average Diluted Shares Outstanding | 35.82M | 35.79M | 35.03M | 34.24M | 34.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |